Use: Labeled indications
- INDICATIONS AND USAGE Tretinoin is indicated for topical application in the treatment of acne vulgaris.
Full indications and usage US FDA label
INDICATIONS AND USAGE Tretinoin is indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.
Contraindications
CONTRAINDICATIONS Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Tretinoin Cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.
Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.
Therapeutic results should be noticed after 2 to 3 weeks but more than 6 weeks of therapy may be required before definite beneficial effects are seen. Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms. Patients treated with tretinoin acne treatment may use cosmetics, but the area to be treated should be cleansed thoroughly before the medication is applied (see PRECAUTIONS).
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Topical cream: 1 mg/g, 250 mcg/g, 500 mcg per g, 500 mcg/g
- Cream: 0.06 mcg (0.006 % w/w) per 100 g, 6 mg (0.006 % w/w) per 100 g, 250 mcg/g, 500 mcg/g
- Topical solution: 100 mcg per mL, 250 mcg/mL, 500 mcg/mL
- Capsule: 10 mg
- Per gram topical cream: 250 mcg
Registered products in the Philippines
31 products registered with the Food and Drug Administration (FDA) Philippines list Tretinoin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products31
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcnecareTretinoin | 250 mcg/g (0.025% w/w) CreamAluminum Collapsible Tube x 10 g with cap (Box of 1's) | HRVAT-exempt | Yash Medicare Private LimitedIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRHR-1936 | Jul 31, 2029 | |
Acnoin-TTretinoin | 500 mcg/g (0.05%) CreamPlastic Tube (70% LDPE, 25% LLDPE and 5% HDPE) x 30g (Box of 1's) | RxVAT-exempt | Zee LaboratoriesIndia | EON Pharmatek, Inc | DRP-15019 | Jun 8, 2031 | |
Age Defying CreamTretinoin | 500 mcg/g (0.05% w/w) CreamPlastic Tube x 30 g (Box of 1's) | RxVAT-exempt | Zee LaboratoriesIndia | Intelligent Beauty Skin Solutions, Inc.Importer: Eon Pharmatek Inc. | DR-XY47305 | Jun 18, 2031 | |
Beautamin-A 0.025%Tretinoin | 250 mcg/g (0.025% w/w) Topical CreamLDPE Aluminum Squeezable Tube with nozzle & cap x 10g and 30g (Box of I's) | HRVAT-exempt | Carmel Laboratories, Inc.Philippines | Trader: A.R.M. Skin Essentials, Corp | HRP-543 | Sep 14, 2027 | |
Beautederm Night Cream 1Tretinoin | 6 mg (0.006% w/w) per 100 g CreamPET Jar with Cap x 20 | HRVAT-exempt | DJM Grandeur CorporationPhilippines | Trader: Perfectskin Beauty Products Inc. | HRP-485 | Nov 24, 2026 | |
Beutamin-A 0.05%Tretinoin | 500mcg per g (0.05% w/w) Topical CreamLDPE Aluminum Squeezable Tube x 10g and 30g with Nozzle and Cover (Box of 1s') | HRVAT-exempt | Carmel Laboratories, Inc.Philippines | Trader: A.R.M. Skin Essentials Corp. | HRP-547 | Sep 23, 2027 | |
Blanc By Beautederm Acne BanishingTretinoin | 0.06 mcg (0.006% w/w) per 100 g CreamPP JAR WITH COVER, 5 AND 10 G | OTCVAT-exempt | DJM Grandeur CorporationPhilippines | Trader: Beautederm Corporation | DRP-12019 | May 31, 2027 | |
Dermese-ATretinoin | 0.05% Gel10g Aluminum Collapsible Tube Not applicable | RxVAT-exempt | MCB Dermatological ProductsPhilippines | — | DR-XY26634 | Oct 16, 2030 | |
Dermese-ATretinoin | 500 mcg/g (0.05%) Cream10 g Aluminum Tube with HDPE Screw Cap (Box of 1's) | HRVAT-exempt | MCB DERMATOLOGICAL PRODUCTSPhilippines | — | DRHR-1721 | Aug 21, 2028 | |
NoneTretinoin | 0.025% Topical Cream500g HDPE Jar with PP Cap | RxVAT-exempt | STALDER LABORATORIES, INC.Philippines | Trader: BCP DERMATOLOGICAL CORP. | DR-XY38759 | Nov 18, 2027 | |
NoneTretinoin | 0.05% w/w CreamAluminum Collapsible Tube x 10 g (Box of 1's); Aluminum Collapsible Tube x 3.5 g (Physician's Sample) | RxVAT-exempt | Stalder Laboratories, Inc.Philippines | BCP Dermatological Corporation | DRP-5856 | May 19, 2031 | |
NoneTretinoin | 100 mcg per mL (0.01% w/v) Topical SolutionPET Bottle x 60 mL | HRVAT-exempt | Altum International Cosmeceutical Manufacturing Inc.Philippines | — | DRHR-2356 | May 10, 2029 | |
NoneTretinoin | 100 mcg per mL (0.01% w/v) Topical SolutionPET Bottle x 60mL | HRVAT-exempt | Altum International Cosmeceutical Manufacturing Inc.Philippines | — | HRP-658 | May 10, 2029 | |
NoneTretinoin | 250 mcg / g (0.025% w/w) Topical CreamPET Jar x 10 g | HRVAT-exempt | Altum International Cosmeceutical Manufacturing Inc.Philippines | — | HRP-657 | May 10, 2029 | |
NoneTretinoin | 250 mcg/g (0.025% w/w) Topical CreamPET Jar x 10 g | HRVAT-exempt | Altum International Cosmeceutical Manufacturing Inc.Philippines | — | DRHR-2359 | May 10, 2029 | |
NoneTretinoin | 500 mcg/g (0.05% w/w) CreamPolypropylene (PP) Micro-Oval Bottle x 25 g (Box of 1's) | RxVAT-exempt | Gruppo Medica, Inc.Philippines | Trader: Time Machine Cosmetiques, Inc. | DR-XY33436 | Jun 6, 2029 | |
NoneTretinoin | 500 mcg/g (0.05% w/w) Topical CreamHDPE Jar with PP Cap x 500 g | RxVAT-exempt | Stalder Laboratories, Inc.Philippines | Trader: BCP Dermatological Corp. | DR-XY38758 | Nov 18, 2027 | |
NoneTretinoin | 500 mcg/mL (0.05%) Topical SolutionHDPE Bottle with screw cap x 50 mL and 100 mL Not Applicable | RxVAT-exempt | MCB Dermatological ProductsPhilippines | — | DR-XY46841 | Mar 12, 2031 | |
NuDerm DermageTretinoin | 1 mg/g (0.1% w/w) Topical CreamAluminum Tube with Plastic Screw Cap x 20 g Box of 1's | OTCVAT-exempt | Derm Pharma, Inc.Philippines | — | DR-XY29256 | Sep 13, 2027 | |
Oroderm Facial SolutionTretinoin | 250 mcg/mL (0.025% w/v) Topical SolutionAmber Glass Bottle x 60 mL (Box of 1s) | OTCVAT-exempt | Oroderm CorporationPhilippines | — | DRHR-2074 | Nov 3, 2031 | |
Oroderm Night CreamTretinoin | 500 mcg/g (0.05% w/w) CreamPP Jar x 15 g | OTCVAT-exempt | Oroderm CorporationLaguna | — | DRHR-2075 | Nov 3, 2031 | |
RetacnylTretinoin | 500 mcg/g (0.05%) CreamAluminum Tube x 30 g (Box of 1's) | OTCVAT-exempt | Laboratoires GaldermaFrance | Galderma Philippines, Inc. | DR-XY20156 | Mar 12, 2031 | |
SaphtinoinTretinoin | 250 mcg/g (0.025% w/w) Topical CreamCollapsible Aluminum Tube x 5 g, 10 g and 15 g (Box of l's) | OTCVAT-exempt | Azine Healthcare Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10842 | Dec 6, 2026 | |
TreanTretinoin | 250 mcg/g (0.025% w/w) CreamLaminated Tube x 15g With White Plastic Cap (Box of 1's) | RxVAT-exempt | Zhejiang Jingwei Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | HRP-433 | Jun 25, 2031 | |
TretinonTretinoin | 500 mcg/g (0.05% w/w) Topical CreamAluminum Tube x 20 g (Box of 1's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY47594 | Dec 9, 2031 | |
TrexonylTretinoin | 500 mcg/g (0.05% w/w) Topical CreamLami tube x 30 g (Box of 1’s) | HRVAT-exempt | Nanz Med Science Pharma Pvt. Ltd.India | Pharma-Surrey International Inc. | HRP-753 | Aug 5, 2031 | |
TrunexTretinoin | 250 mcg/g (0.025% w/w) Topical CreamLaminated Tube x 15g (Box of 1's) | HRVAT-exempt | KLM Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | HRP-708 | Sep 24, 2030 | |
TrunexTretinoin | 500 mcg/g (0.05% w/w) Topical CreamLaminated Tube x 15g (Box of 1's) | HRVAT-exempt | KLM Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | HRP-709 | Sep 24, 2030 | |
UnbrandedTretinoin | 0.025% w/w CreamAluminum Collapsible Tube x 10 g (Box of 1's); Aluminum Collapsible Tube x 3.5 g (Physician's Sample) | RxVAT-exempt | Stalder Laboratories, Inc.Laguna | Trader: BCP Dermatological Corporation | DRP-5855 | May 19, 2031 | |
VesanoidTretinoin | 10 mg CapsuleAmber Glass Bottle x 100's (In a box) | RxVAT-exempt | Cheplapharm Arzneimittel GmBHGermany | Zuellig Pharma Corporation | DR-XY18526 | Aug 10, 2027 | |
(no brand name)Tretinoin | 250 mcg (0.025% w/w) per gram Topical CreamHDPE Aluminum Collapsible Tube with Cap x 10 g & 20 g (Box of l's) | HRVAT-exempt | MCB Dermatological ProductsPhilippines | — | DRHR-2099 | Nov 19, 2026 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
PRECAUTIONS General If a reaction suggesting sensitivity or chemical irritation occurs, use of the medication should be discontinued. Exposure to sunlight, including sunlamps, should be minimized during the use of tretinoin, and patients with sunburn should be advised not to use the product until fully recovered because of heightened susceptibility to sunlight as a result of the use of tretinoin.
Patients who may be required to have considerable sun exposure due to occupation and those with inherent sensitivity to the sun should exercise particular caution. Use of sunscreen products and protective clothing over treated areas is recommended when exposure cannot be avoided. Weather extremes, such as wind or cold, also may be irritating to patients under treatment with tretinoin.
Tretinoin acne treatment should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. Topical use may induce severe local erythema and peeling at the site of application. If the degree of local irritation warrants, patients should be directed to use the medication less frequently, discontinue use temporarily, or discontinue use altogether.
Tretinoin has been reported to cause severe irritation on eczematous skin and should be used with utmost caution in patients with this condition. Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin.
Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun. Carcinogenesis, Mutagenesis, Impairment to Fertility In a 91-week dermal study in which CD-1 mice were administered 0.017% and 0.035% formulations of tretinoin, cutaneous squamous cell carcinomas and papillomas in the treatment area were observed in some female mice.
A dose-related incidence of liver tumors in male mice was observed at those same doses. The maximum systemic doses associated with the administered 0.017% and 0.035% formulations are 0.5 and 1.0 mg/kg/day, respectively. These doses are two and four times the maximum human systemic dose, when adjusted for total body surface area.
The biological significance of these findings is not clear because they occurred at doses that exceeded the dermal maximally tolerated dose (MTD) of tretinoin and because they were within the background natural occurrence rate for these tumors in this strain of mice. There was no evidence of carcinogenic potential when 0.025 mg/kg/day of tretinoin was administered topically to mice (0.1 times the maximum human systemic dose, adjusted for total body surface area).
For purposes of comparisons of the animal exposure to systemic human exposure, the maximum human systemic dose is defined as 1 gram of 0.1% RETIN-A applied daily to a 50 kg person (0.02 mg tretinoin/kg body weight). Studies in hairless albino mice suggest that concurrent exposure to tretinoin may enhance the tumorigenic potential of carcinogenic doses of UVB and UVA light from a solar simulator.
This effect has been confirmed in a later study in pigmented mice, and dark pigmentation did not overcome the enhancement of photocarcinogenesis by 0.05% tretinoin. Although the significance of these studies to humans is not clear, patients should minimize exposure to sunlight or artificial ultraviolet irradiation sources.
The mutagenic potential of tretinoin was evaluated in the Ames assay and in the in vivo mouse micronucleus assay, both of which were negative. In dermal Segment I fertility studies of another tretinoin formulation in rats, slight (not statistically significant) decreases in sperm count and motility were seen at 0.5 mg/kg/day (4 times the maximum human systemic dose adjusted for total body surface area) and slight (not statistically significant) increases in the number and percent of nonviable embryos in females treated with 0.25 mg/kg/day (2 times the maximum human systemic dose adjusted for total body surface area) and above were observed.
A dermal Segment III study with RETIN-A has not been performed in any species. In oral Segment I and Segment III studies in rats with tretinoin, decreased survival of neonates and growth retardation were observed at doses in excess of 2 mg/kg/day (16 times the human topical dose adjusted for total body surface area). Pregnancy Teratogenic Effects Oral tretinoin has been shown to be teratogenic in rats, mice, hamsters, and subhuman primates.
It was teratogenic and fetotoxic in Wistar rats when given orally or topically in doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). However, variations in teratogenic doses among various strains of rats have been reported. In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than the other species examined, fetal malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human systemic dose adjusted for total body surface area), although increased skeletal variations were observed at all doses.
A dose-related increase in embryolethality and abortion was reported. Similar results have also been reported in pigtail macaques. Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area).
Anomalies (humerus: short 13%, bent 6%, os parietale incompletely ossified 14%) have also been reported when 10 mg/kg/day was topically applied. There are other reports in New Zealand White rabbits administered doses of greater than 0.2 mg/kg/day (3.3 times the maximum human systemic dose adjusted for total body surface area) of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.
In contrast, several well-controlled animal studies have shown that dermally applied tretinoin may be fetotoxic, but not overly teratogenic in rats and rabbits at doses of 1.0 and 0.5 mg/kg/day, respectively (8 times the maximum human systemic dose adjusted for total body surface area in both species). With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone.
Thirty human cases of temporally associated congenital malformations have been reported during two decades of clinical use of RETIN-A. Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category holoprosencephaly (defects associated with incomplete midline development of the forebrain).
The significance of these spontaneous reports in terms of risk to the fetus is not known. Nonteratogenic Effects Topical tretinoin has been shown to be fetotoxic in rabbits when administered 0.5 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased intrauterine death in rats when administered 2.5 mg/kg/day (20 times the maximum human systemic dose adjusted for total body surface area).
There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman.
Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use Safety and effectiveness in a geriatric population have not been established. Clinical studies of RETIN-A did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin is begun.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered.
Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see DOSAGE AND ADMINISTRATION).
To report SUSPECTED ADVERSE REACTIONS, contact Obagi Cosmeceuticals LLC at 1-800-636-7546 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Oral tretinoin has been shown to be teratogenic in rats, mice, hamsters, and subhuman primates. It was teratogenic and fetotoxic in Wistar rats when given orally or topically in doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). However, variations in teratogenic doses among various strains of rats have been reported.
In the cynomolgus monkey, which metabolically is closer to humans for tretinoin than the other species examined, fetal malformations were reported at doses of 10 mg/kg/day or greater, but none were observed at 5 mg/kg/day (83 times the maximum human systemic dose adjusted for total body surface area), although increased skeletal variations were observed at all doses. A dose-related increase in embryolethality and abortion was reported.
Similar results have also been reported in pigtail macaques. Topical tretinoin in animal teratogenicity tests has generated equivocal results. There is evidence for teratogenicity (shortened or kinked tail) of topical tretinoin in Wistar rats at doses greater than 1 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area).
Anomalies (humerus: short 13%, bent 6%, os parietale incompletely ossified 14%) have also been reported when 10 mg/kg/day was topically applied. There are other reports in New Zealand White rabbits administered doses of greater than 0.2 mg/kg/day (3.3 times the maximum human systemic dose adjusted for total body surface area) of an increased incidence of domed head and hydrocephaly, typical of retinoid-induced fetal malformations in this species.
In contrast, several well-controlled animal studies have shown that dermally applied tretinoin may be fetotoxic, but not overly teratogenic in rats and rabbits at doses of 1.0 and 0.5 mg/kg/day, respectively (8 times the maximum human systemic dose adjusted for total body surface area in both species). With widespread use of any drug, a small number of birth defect reports associated temporally with the administration of the drug would be expected by chance alone.
Thirty human cases of temporally associated congenital malformations have been reported during two decades of clinical use of RETIN-A. Although no definite pattern of teratogenicity and no causal association have been established from these cases, five of the reports describe the rare birth defect category holoprosencephaly (defects associated with incomplete midline development of the forebrain).
The significance of these spontaneous reports in terms of risk to the fetus is not known. Nonteratogenic Effects Topical tretinoin has been shown to be fetotoxic in rabbits when administered 0.5 mg/kg/day (8 times the maximum human systemic dose adjusted for total body surface area). Oral tretinoin has been shown to be fetotoxic, resulting in skeletal variations and increased intrauterine death in rats when administered 2.5 mg/kg/day (20 times the maximum human systemic dose adjusted for total body surface area).
There are, however, no adequate and well-controlled studies in pregnant women. Tretinoin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tretinoin is administered to a nursing woman. Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 have not been established. Geriatric Use Safety and effectiveness in a geriatric population have not been established. Clinical studies of RETIN-A did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Although the exact mode of action of tretinoin is unknown, current evidence suggests that topical tretinoin decreases cohesiveness of follicular epithelial cells with decreased microcomedo formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells causing extrusion of the comedones.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Tretinoin Cream · Obagi Cosmeceuticals LLC [US FDA-approved label, version 13, February 11, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=745cc3ce-60b4-4479-a055-316817567949
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .